Harold Mastalerz
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Synthetic Organic Chemistry Methods, Synthesis of β-Lactam Compounds, Steroid Chemistry and Biochemistry, Synthesis and biological activity
Most-Cited Works
- → Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains(2002)134 cited
- → Discovery of a 2,4-Disubstituted Pyrrolo[1,2-f][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development(2009)94 cited
- → Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling(2006)79 cited
- → Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages(2002)50 cited
- → An examination of O-2-isocephems as orally absorbable antibiotics(1988)48 cited
- → The discovery of BMS-275183: an orally efficacious novel taxane(2003)47 cited
- → New dual inhibitors of EGFR and HER2 protein tyrosine kinases(2005)44 cited
- → New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases(2007)38 cited
- → Palladium-catalyzed conversion of esters of 4-(trimethylsilyl)-2-buten-1-ol to trimethylsilyl esters: a new carboxyl protecting group(1984)37 cited
- → 5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases(2007)30 cited